Jim Simons Anixa Biosciences Inc Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 68,800 shares of ANIX stock, worth $169,936. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,800

Holding current value

$169,936

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$3.08 - $5.02 $211,904 - $345,375	68,800 New	68,800 $215,000
Q3 2023 Nov 14, 2023	SELL	$2.97 - $3.87 $146,421 - $190,791	-49,300 Reduced 83.14%	10,000 $33,000
Q2 2023 Aug 11, 2023	BUY	$3.0 - $5.97 $113,994 - $226,848	37,998 Added 178.38%	59,300 $190,000
Q1 2023 May 12, 2023	SELL	$3.86 - $5.0 $102,668 - $132,990	-26,598 Reduced 55.53%	21,302 $92,000
Q4 2022 Feb 13, 2023	SELL	$3.78 - $5.63 $35,154 - $52,359	-9,300 Reduced 16.26%	47,900 $204,000

Q3 2022 Nov 14, 2022	SELL	$2.81 - $6.15 $80,596 - $176,394	-28,682 Reduced 33.4%	57,200 $281,000
Q2 2022 Aug 12, 2022	SELL	$2.55 - $4.1 $353,871 - $568,969	-138,773 Reduced 61.77%	85,882 $263,000
Q1 2022 May 13, 2022	SELL	$2.5 - $3.42 $265,362 - $363,015	-106,145 Reduced 32.09%	224,655 $616,000
Q4 2021 Feb 11, 2022	BUY	$2.88 - $5.5 $341,568 - $652,300	118,600 Added 55.89%	330,800 $982,000
Q3 2021 Nov 12, 2021	BUY	$3.57 - $5.6 $313,092 - $491,125	87,701 Added 70.44%	212,200 $1.01 Million
Q2 2021 Aug 13, 2021	BUY	$3.46 - $4.92 $430,766 - $612,535	124,499 New	124,499 $483,000
Q2 2020 Aug 13, 2020	SELL	$1.53 - $3.06 $49,290 - $98,580	-32,216 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$1.35 - $4.06 $43,491 - $130,796	32,216 New	32,216 $51,000

Others Institutions Holding ANIX

# of Institutions

Shares Held

5.16M

Call Options Held

14.5K

Put Options Held

24.3K

View Full List

About Anixa Biosciences Inc

Ticker ANIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,661,700
Market Cap $75.7M
Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...

More about ANIX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account